全文获取类型
收费全文 | 7071篇 |
免费 | 370篇 |
国内免费 | 80篇 |
专业分类
耳鼻咽喉 | 61篇 |
儿科学 | 129篇 |
妇产科学 | 86篇 |
基础医学 | 899篇 |
口腔科学 | 149篇 |
临床医学 | 417篇 |
内科学 | 2117篇 |
皮肤病学 | 131篇 |
神经病学 | 504篇 |
特种医学 | 193篇 |
外科学 | 986篇 |
综合类 | 48篇 |
预防医学 | 223篇 |
眼科学 | 106篇 |
药学 | 520篇 |
中国医学 | 8篇 |
肿瘤学 | 944篇 |
出版年
2023年 | 29篇 |
2022年 | 35篇 |
2021年 | 139篇 |
2020年 | 104篇 |
2019年 | 126篇 |
2018年 | 201篇 |
2017年 | 149篇 |
2016年 | 149篇 |
2015年 | 180篇 |
2014年 | 249篇 |
2013年 | 314篇 |
2012年 | 483篇 |
2011年 | 559篇 |
2010年 | 302篇 |
2009年 | 243篇 |
2008年 | 441篇 |
2007年 | 511篇 |
2006年 | 478篇 |
2005年 | 445篇 |
2004年 | 463篇 |
2003年 | 433篇 |
2002年 | 475篇 |
2001年 | 70篇 |
2000年 | 46篇 |
1999年 | 77篇 |
1998年 | 92篇 |
1997年 | 66篇 |
1996年 | 76篇 |
1995年 | 81篇 |
1994年 | 66篇 |
1993年 | 61篇 |
1992年 | 52篇 |
1991年 | 33篇 |
1990年 | 27篇 |
1989年 | 36篇 |
1988年 | 27篇 |
1987年 | 27篇 |
1986年 | 20篇 |
1985年 | 19篇 |
1984年 | 19篇 |
1983年 | 13篇 |
1982年 | 13篇 |
1981年 | 15篇 |
1980年 | 17篇 |
1979年 | 9篇 |
1978年 | 8篇 |
1977年 | 5篇 |
1976年 | 9篇 |
1975年 | 7篇 |
1965年 | 4篇 |
排序方式: 共有7521条查询结果,搜索用时 15 毫秒
1.
2.
Norito Katoh Hidehisa Saeki Yoko Kataoka Takafumi Etoh Satoshi Teramukai Hiroki Takagi Yuki Tajima Marius Ardeleanu Elena Rizova Kazuhiko Arima 《The Journal of dermatology》2019,46(4):290-300
Moderate to severe atopic dermatitis (AD) has a high disease burden and a significant effect on quality of life. Observational studies are necessary to determine the patient disease burden and long‐term disease control in the Japanese population. ADDRESS‐J is a non‐interventional, observational registry of adult Japanese patients with moderate to severe AD. Herein, we report baseline data from the ADDRESS‐J study describing disease characteristics and current treatment practices. At baseline, 300 adult AD patients with Investigator's Global Assessment (IGA) scores (range, 0–4) of 3 (moderate) or 4 (severe) whose treatments for AD were intensified, were assessed for clinical and patient‐reported outcomes and current AD treatments. The registry patients’ median age was 34.0 years; 60.7% were male and 71.7% had had AD for more than 20 years. At baseline, 220 study patients had an IGA score of 3 and 80 had an IGA score of 4. The median Eczema Area and Severity Index score was 21.7 (range, 0–72), the median body surface area involvement was 46.25%, and the median pruritus numerical rating scale score was 7.0 (range, 0–10); for each of these measures, higher scores represent greater severity. Most registry patients (86.7%) had recently used topical corticosteroids or topical calcineurin inhibitors as treatment for AD. This registry cohort represents a population of Japanese patients with moderate to severe AD and provides an important resource for characterizing the disease burden and evaluating the safety and effectiveness of various AD treatments. 相似文献
3.
4.
5.
Sarina A. Piha-Paul Do-Youn Oh Makoto Ueno David Malka Hyun Cheol Chung Adnan Nagrial Robin K. Kelley Willeke Ros Antoine Italiano Kazuhiko Nakagawa Hope S. Rugo Filippo de Braud Andrea Iolanda Varga Aaron Hansen Hui Wang Suba Krishnan Kevin G. Norwood Toshihiko Doi 《International journal of cancer. Journal international du cancer》2020,147(8):2190-2198
We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE-158 (NCT02628067; phase 2) and KEYNOTE-028 (NCT02054806; phase 1b) studies. Eligible patients aged ≥18 years from both studies had histologically/cytologically confirmed incurable BTC that progressed after standard treatment regimen(s), measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status 0/1, and no prior immunotherapy. Programmed death ligand 1 (PD-L1)-positive tumors were required for eligibility in KEYNOTE-028 only. Patients received pembrolizumab 200 mg every three weeks (KEYNOTE-158) or 10 mg/kg every two weeks (KEYNOTE-028) for ≤2 years. Primary efficacy endpoint was objective response rate (ORR) by RECIST v1.1. Response assessed by independent central review is reported. KEYNOTE-158 enrolled 104 patients and KEYNOTE-028 enrolled 24 patients. Median (range) follow-up was 7.5 months (0.6-34.3) in KEYNOTE-158 and 5.7 months (0.6-55.4) in KEYNOTE-028. In KEYNOTE-158, ORR was 5.8% (6/104; 95% CI, 2.1%-12.1%); median duration of response (DOR) was not reached (NR) (range, 6.2-26.6+ months). Median (95% CI) OS and PFS were 7.4 (5.5-9.6) and 2.0 (1.9-2.1) months. Among PD-L1-expressers (n = 61) and PD-L1-nonexpressers (n = 34), respectively, ORR was 6.6% (4/61) and 2.9% (1/34). In KEYNOTE-028, ORR was 13.0% (3/23; 95% CI, 2.8%-33.6%); median DOR was NR (range, 21.5-53.2+ months). Median (95% CI) OS and PFS were 5.7 (3.1-9.8) and 1.8 (1.4-3.1) months. Grade 3 to 5 treatment-related adverse events occurred in 13.5% of patients in KEYNOTE-158 (no grade 4; grade 5 renal failure, n = 1) and 16.7% in KEYNOTE-028 (no grade 4/5). In summary, pembrolizumab provides durable antitumor activity in 6% to 13% of patients with advanced BTC, regardless of PD-L1 expression, and has manageable toxicity. 相似文献
6.
7.
8.
9.
10.